ZBH Quote, Financials, Valuation and Earnings

Edwards Lifesciences has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of 25.34%. Zimmer Biomet Holdings's return on equity of 7.29% beat Edwards Lifesciences's return on equity of 46.91%.

Zimmer Biomet Holdings has a consensus price target of $109.74, signalling upside risk potential of 20.26%. On the other hand Edwards Lifesciences has an analysts' consensus of $80.28 which suggests that it could grow by 7.01%. Given that Zimmer Biomet Holdings has higher upside potential than Edwards Lifesciences, analysts believe Zimmer Biomet Holdings is more attractive than Edwards Lifesciences.

Zimmer Biomet Holdings has a beta of 0.780, which suggesting that the stock is 21.988% less volatile than S&P 500. In comparison Edwards Lifesciences has a beta of 1.124, suggesting its more volatile than the S&P 500 by 12.434%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.04%. Edwards Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Edwards Lifesciences pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $1.9B, which are larger than Edwards Lifesciences quarterly revenues of $1.4B. Zimmer Biomet Holdings's net income of $182M is lower than Edwards Lifesciences's net income of $358M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.41x while Edwards Lifesciences's PE ratio is 10.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.42x versus 8.06x for Edwards Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of -211%. Zimmer Biomet Holdings's return on equity of 7.29% beat Nutriband's return on equity of -69.58%.

Zimmer Biomet Holdings has a consensus price target of $109.74, signalling upside risk potential of 20.26%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 124.91%. Given that Nutriband has higher upside potential than Zimmer Biomet Holdings, analysts believe Nutriband is more attractive than Zimmer Biomet Holdings.

Zimmer Biomet Holdings has a beta of 0.780, which suggesting that the stock is 21.988% less volatile than S&P 500. In comparison Nutriband has a beta of 1.185, suggesting its more volatile than the S&P 500 by 18.545%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.04%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $1.9B, which are larger than Nutriband quarterly revenues of $645.8K. Zimmer Biomet Holdings's net income of $182M is higher than Nutriband's net income of -$1.4M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.41x while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.42x versus 28.66x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

Steris PLC has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of 12.66%. Zimmer Biomet Holdings's return on equity of 7.29% beat Steris PLC's return on equity of 7.27%.

Zimmer Biomet Holdings has a consensus price target of $109.74, signalling upside risk potential of 20.26%. On the other hand Steris PLC has an analysts' consensus of $250.11 which suggests that it could grow by 12.44%. Given that Zimmer Biomet Holdings has higher upside potential than Steris PLC, analysts believe Zimmer Biomet Holdings is more attractive than Steris PLC.

Zimmer Biomet Holdings has a beta of 0.780, which suggesting that the stock is 21.988% less volatile than S&P 500. In comparison Steris PLC has a beta of 0.956, suggesting its less volatile than the S&P 500 by 4.397%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.04%. Steris PLC offers a yield of 1% to investors and pays a quarterly dividend of $0.57 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Steris PLC pays out 53.03% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $1.9B, which are larger than Steris PLC quarterly revenues of $1.4B. Zimmer Biomet Holdings's net income of $182M is higher than Steris PLC's net income of $173.5M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.41x while Steris PLC's PE ratio is 47.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.42x versus 4.09x for Steris PLC. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 9.53% compared to Zimmer Biomet Holdings's net margin of 11.15%. Zimmer Biomet Holdings's return on equity of 7.29% beat Stryker's return on equity of 14.2%.

Zimmer Biomet Holdings has a consensus price target of $109.74, signalling upside risk potential of 20.26%. On the other hand Stryker has an analysts' consensus of $424.26 which suggests that it could grow by 12.38%. Given that Zimmer Biomet Holdings has higher upside potential than Stryker, analysts believe Zimmer Biomet Holdings is more attractive than Stryker.

Zimmer Biomet Holdings has a beta of 0.780, which suggesting that the stock is 21.988% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.091%.

Zimmer Biomet Holdings has a quarterly dividend of $0.24 per share corresponding to a yield of 1.04%. Stryker offers a yield of 0.87% to investors and pays a quarterly dividend of $0.84 per share. Zimmer Biomet Holdings pays 21.69% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Zimmer Biomet Holdings quarterly revenues are $1.9B, which are smaller than Stryker quarterly revenues of $5.9B. Zimmer Biomet Holdings's net income of $182M is lower than Stryker's net income of $654M. Notably, Zimmer Biomet Holdings's price-to-earnings ratio is 20.41x while Stryker's PE ratio is 51.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zimmer Biomet Holdings is 2.42x versus 6.27x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.